In rodent models of PAH, recombinant human ACE2 has been shown to treat established PAH, including bone morphogenetic protein receptor type II mutation‐related PAH17 and pulmonary artery banding models.18 This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.